Elsevier Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Scordo
    Scordo
  4. Shah
    Shah
  5. Ponce
    Ponce
  6. Dahi
    Dahi
  7. Papadopoulos
    Papadopoulos
  8. Jakubowski
    Jakubowski
  9. Devlin
    Devlin
  10. Castro-Malaspina
    Castro-Malaspina

Groups

  1. CTCR Scholars (390)
  2. Department of Medicine (348)
  3. Hematologic Malignancies, Division of (318)
  4. Center for Hematologic Malignancies (303)
  5. Bone Marrow Transplant (296)
  6. Survivorship Research (274)
  7. MSK Grad Students (225)
  8. Master of Science in Clinical and Translational Cancer Research (219)
  9. Epidemiology and Biostatistics (165)
  10. Biostatistics Service (162)
Search Within
  1. "CTCR Scholars"
Formats
  1. Meeting Abstract (252)
  2. Journal Article (110)
  3. Review (15)
  4. Guidelines (5)
  5. Book Section (3)
  6. Editorial (3)
  7. Correspondence (1)
  8. Research Letter (1)
Groups
  1. CTCR Scholars (390)
  2. Department of Medicine (348)
  3. Hematologic Malignancies, Division of (318)
  4. Center for Hematologic Malignancies (303)
  5. Bone Marrow Transplant (296)
  6. Survivorship Research (274)

More Groups

People
  1. Sergio Giralt (219)
  2. Miguel-Angel Perales (146)
  3. Michael Scordo (121)
  4. Sean Devlin (118)
  5. Gunjan Shah (114)
  6. Doris Ponce (108)

More People

Years
  1. 2025 (9)
  2. 2024 (36)
  3. 2023 (45)
  4. 2022 (56)
  5. 2021 (22)
  6. 2020 (59)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (187)
  2. Transplantation and Cellular Therapy (55)
  3. Gynecologic Oncology (50)
  4. Clinical Lymphoma, Myeloma and Leukemia (48)
  5. International Journal of Radiation Oncology, Biology, Physics (16)
  6. Journal of Thoracic Oncology (6)

More Publications

Results (390)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; GarceĢs, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of olomorasib with pembrolizumab + chemotherapy as first-line treatment in patients with KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Fujiwara, Y.; Reddy Ammakkanavar, N.; Hollebecque, A.; Murciano-Goroff, Y. R.; Lee, D. H.; Burns, T. F.; Cassier, P.; Han, J. Y.; Italiano, A.; Koyama, T.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma
    Journal Article

    Lorenc, R.; Shouval, R.; Flynn, J. R.; Devlin, S. M.; Saldia, A.; Luna De Abia, A.; De Lapuerta, M. C.; Tomas, A. A.; Cassanello, G.; Leslie, L. A.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: A pharmacovigilance analysis of the FDA Reporting System
    Journal Article

    Storgard, R.; Dusza, S.; Shouval, R.; Scordo, M.; Markova, A.
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • In pursuit of optimal outcomes: A framework for quality standards in immune effector cell therapy
    Editorial

    Dandoy, C. E.; Adams, J.; Artz, A.; Bredeson, C.; Dahi, P. B.; Dodd, T.; Jaglowski, S.; Lehmann, L.; LeMaistre, C. F.; Mian, A.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer
    Journal Article

    Liu, S. Y.; Erazo, T.; Jee, J.; Arfe, A.; Gupta, A.; Pike, L. R. G.; Santini, F. C.; Daly, B.; Schoenfeld, A.; Eichholz, J.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save